Ahpra registration PHY0002298174
How these guides are written and reviewed →
Heart muscle cells contain a protein called dystrophin that acts as internal scaffolding, letting the cell contract thousands of times a day without tearing itself apart. Faults in the gene for dystrophin usually cause Duchenne muscular dystrophy, which affects the skeletal muscles and the heart together. In X-linked dilated cardiomyopathy the same gene is faulty but the effect falls almost entirely on the heart: the walls stretch and thin, and the pump weakens, while the arm and leg muscles stay essentially normal. Because the gene sits on the X chromosome, it runs through families in a particular pattern.
Definition
X-linked dilated cardiomyopathy (XLDCM) is an inherited heart muscle disease caused by variants in the dystrophin gene (DMD) on the X chromosome, in which the heart dilates and weakens without the skeletal muscle weakness that characterises Duchenne muscular dystrophy.1,2,3
Linkage to the dystrophin locus was established in 1993, and in the same year deletions affecting the muscle promoter region of the gene were shown to produce cardiac disease while sparing skeletal muscle.1,2 That mechanism — a fault that silences dystrophin in the heart while allowing alternative promoters to maintain it in skeletal muscle — explains the whole clinical picture.3
It sits within the wider group of genetic dilated cardiomyopathies, of which a considerable proportion have an identifiable genetic cause.4
Pathophysiology
What dystrophin does
Dystrophin links the internal skeleton of the muscle cell to the membrane and the surrounding matrix, distributing the mechanical stress of each contraction. Without it, the membrane is damaged with repeated contraction, calcium enters abnormally, and cells die and are replaced by fibrous tissue.3,4
Why the heart alone
The dystrophin gene has several tissue-specific promoters. Variants that remove or disable the muscle promoter can leave the brain and Purkinje promoters able to compensate in skeletal muscle, but not in cardiac muscle — producing heart disease in isolation.2,3
The consequence
Progressive loss of cardiac muscle leads to a dilated, thin-walled left ventricle that contracts poorly. Fibrosis accumulates in a characteristic distribution, often beginning in the outer layer of the lateral wall — a pattern visible on MRI and associated with adverse outcome.10
Inheritance
This is the part families most need explained clearly.9
- Males have one X chromosome, so a single faulty copy produces disease. They are typically affected in adolescence or early adulthood, and the disease progresses relatively rapidly.1,3
- Females have two X chromosomes and are usually described as carriers, but this is misleading if taken to mean unaffected. A proportion develop dilated cardiomyopathy themselves, usually later and more slowly, and carrier females warrant lifelong cardiac surveillance rather than reassurance.3,9
- An affected man passes the variant to all his daughters and none of his sons. A carrier woman passes it to half her children of either sex.9
Genetic counselling and cascade screening of relatives are recommended where a cardiomyopathy-causing variant is identified.5,9
Symptoms
- Breathlessness on exertion, then at rest as the condition advances.
- Fatigue and reduced exercise tolerance, often the earliest change and easily attributed to being unfit.6
- Ankle swelling and abdominal fullness.
- Palpitations, and in some cases arrhythmia as a presenting feature.5
- No symptoms at all in relatives identified through family screening, which is increasingly how the diagnosis is first made.9
Skeletal muscle strength is normal or near-normal, although a raised blood creatine kinase is common and can be the clue that points to the dystrophin gene.2,3
Diagnosis
- Echocardiography, showing a dilated left ventricle with reduced systolic function.5
- Cardiac MRI, which characterises fibrosis and its distribution and adds prognostic information beyond ejection fraction alone.10
- Serum creatine kinase, typically elevated even without weakness — an inexpensive test that frequently redirects the diagnostic pathway.2,3
- Genetic testing, now recommended in dilated cardiomyopathy with a suspected inherited basis, and the only way to confirm this specific diagnosis.5,9
- Family screening of first-degree relatives, by clinical assessment and by targeted genetic testing where a variant is known.5,9
Management
There is no dystrophin-directed treatment established for the cardiac-only form. Care follows contemporary heart failure and cardiomyopathy guidance, applied earlier than symptoms alone would prompt.5,6
- Guideline-directed heart failure therapy — the four established drug classes, introduced and titrated as tolerated.6
- Early initiation, since evidence in dystrophinopathy cardiomyopathy supports treating before symptoms appear rather than waiting for them.7
- Arrhythmia monitoring, with defibrillator implantation considered according to cardiomyopathy guidance and fibrosis burden.5,10
- Advanced therapies — transplantation or mechanical support in progressive disease, where the absence of skeletal muscle involvement means candidacy is not limited in the way it is in Duchenne muscular dystrophy.3,5
- Surveillance of carrier females, lifelong.9
Living with it
Two features distinguish this from other heart failure, and both are about family rather than physiology.
The first is that a diagnosis rarely stops at one person. Confirming an inherited variant initiates screening across a family, sometimes identifying disease in relatives who felt entirely well.9
The second is the label carried by female relatives. Being told you are "just a carrier" while also being told you need lifelong cardiac follow-up is a genuinely confusing message, and it is worth asking the cardiologist to state plainly what surveillance is being recommended and why.3,9
Role of the physiotherapist
Diagnosis, medication and device decisions are cardiology work. Where a cardiorespiratory physiotherapist contributes is exercise, and the position here is more nuanced than in ordinary heart failure.
- Supervised exercise where cardiology has approved it. Exercise-based rehabilitation in heart failure improves exercise capacity and quality of life and reduces admission, and this population is generally young enough to benefit substantially.8
- Respecting a genuine theoretical caution. Dystrophin-deficient muscle is vulnerable to contraction-induced damage, and high-intensity eccentric loading is generally avoided in dystrophinopathy on mechanistic grounds. Evidence in the cardiac-only form is absent, so prescription stays moderate and this reasoning is explained rather than hidden.3,7
- Assessing exercise capacity objectively, giving the cardiology team a repeatable measure alongside imaging.6
- Supporting asymptomatic relatives identified by screening, who are often the hardest group to advise — well, active, and newly told their heart is being watched.9
We work from written cardiology advice, and we ask for it before prescribing exertion.
Exercise helps in heart failure, and this group is usually young enough to gain a lot from it. But dystrophin-deficient muscle is vulnerable to contraction damage, so we keep intensity moderate, avoid heavy eccentric loading, and tell you why rather than leaving it unexplained. We also see relatives identified by family screening — well, active, and newly told their heart is being watched.
Part 1 · References
- Towbin JA, Hejtmancik JF, Brink P, et al. X-linked dilated cardiomyopathy: molecular genetic evidence of linkage to the Duchenne muscular dystrophy (dystrophin) gene at the Xp21 locus. Circulation 1993;87(6):1854–1865.
- Muntoni F, Cau M, Ganau A, et al. Deletion of the dystrophin muscle-promoter region associated with X-linked dilated cardiomyopathy. N Engl J Med 1993;329(13):921–925.
- Ferlini A, Sewry C, Melis MA, Mateddu A, Muntoni F. X-linked dilated cardiomyopathy and the dystrophin gene. Neuromuscul Disord 1999;9(5):339–346.
- McNally EM, Mestroni L. Dilated cardiomyopathy: genetic determinants and mechanisms. Circ Res 2017;121(7):731–748.
- Arbelo E, Protonotarios A, Gimeno JR, et al. 2023 ESC Guidelines for the management of cardiomyopathies. Eur Heart J 2023;44(37):3503–3626.
- McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021;42(36):3599–3726.
- Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. Lancet Neurol 2018;17(4):347–361.
- Long L, Mordi IR, Bridges C, et al. Exercise-based cardiac rehabilitation for adults with heart failure. Cochrane Database Syst Rev 2019;1:CD003331.
- Hershberger RE, Givertz MM, Ho CY, et al. Genetic evaluation of cardiomyopathy: a clinical practice resource of the American College of Medical Genetics and Genomics. Genet Med 2018;20(9):899–909.
- Florian A, Ludwig A, Engelen M, et al. Left ventricular systolic function and the pattern of late-gadolinium-enhancement independently and additively predict adverse cardiac events in muscular dystrophy patients. J Cardiovasc Magn Reson 2014;16:81.
Clinical evidence
Part 1 covers the same condition without the technical detail. What follows is the evidence base behind it, written for clinicians — the literature, the reasoning and the gaps.
For clinicians: this summary supports clinical reasoning and is not a protocol. Check current guidelines and local policy before applying it, and read it alongside the key references and guidelines directory.
Framing. X-linked dilated cardiomyopathy is caused by DMD variants that impair cardiac dystrophin expression while sparing skeletal muscle, established by linkage analysis and by identification of muscle-promoter deletions in 1993.1,2 It is a genetically defined subset of dilated cardiomyopathy, and management sits within the 2023 ESC cardiomyopathy framework rather than in a condition-specific guideline.4,5
The genotype explains the tissue selectivity, and that has clinical consequences
Tissue-specific promoter usage accounts for cardiac-restricted disease: loss of the muscle promoter can be compensated in skeletal muscle by alternative promoters but not in myocardium.2,3 The diagnostically useful corollary is that creatine kinase is commonly elevated without weakness, and an unexplained raised CK in a young man with dilated cardiomyopathy should prompt consideration of a dystrophinopathy rather than reassurance.2,3
Carrier females are not unaffected
A meaningful proportion of female carriers develop dilated cardiomyopathy, typically later and more slowly than affected males.3 ACMG guidance and ESC cardiomyopathy recommendations therefore support cascade screening and ongoing cardiac surveillance rather than one-off assessment.5,9 The recurring communication failure is the word "carrier", which patients reasonably interpret as meaning they are not at risk.9
Treat early rather than symptomatically
Experience in dystrophinopathy cardiomyopathy supports initiating cardioprotective therapy before symptomatic heart failure develops, and cardiac care recommendations in Duchenne disease are explicit about pre-symptomatic treatment.7 Standard heart failure pharmacotherapy is otherwise as in the 2021 ESC guideline.6 Late gadolinium enhancement pattern and left ventricular function together predict adverse events in muscular dystrophy populations more effectively than function alone, supporting MRI-informed rather than echo-only surveillance.10
Exercise: benefit established in heart failure, caution specific to dystrophin
Exercise-based rehabilitation improves exercise capacity and quality of life in chronic heart failure, with reduced hospitalisation.8 The condition-specific consideration is that dystrophin-deficient sarcolemma is susceptible to contraction-induced injury, which is the mechanistic basis for avoiding high-intensity eccentric loading in dystrophinopathies.3,7 No trial has tested exercise prescription in the cardiac-restricted phenotype, where skeletal muscle expression is preserved and the caution may not apply with equal force — so moderate-intensity prescription with an explicit rationale is the defensible position, not a conservative habit.7,8
What we do not know
- Whether the eccentric-loading caution is warranted in a phenotype with preserved skeletal muscle dystrophin. Untested.3,7,8
- Which carrier females will develop disease, and at what rate — no predictor is established, so surveillance is applied uniformly.3,9
- Whether emerging dystrophin-directed therapies benefit the heart in the cardiac-restricted form; cardiac endpoints have not been the focus of that development.4,7
- Optimal timing of defibrillator implantation, where fibrosis burden and function give partially independent information.5,10
References for the clinical evidence summary
- Towbin JA, Hejtmancik JF, Brink P, et al. X-linked dilated cardiomyopathy: molecular genetic evidence of linkage to the Duchenne muscular dystrophy (dystrophin) gene at the Xp21 locus. Circulation 1993;87(6):1854–1865.
- Muntoni F, Cau M, Ganau A, et al. Deletion of the dystrophin muscle-promoter region associated with X-linked dilated cardiomyopathy. N Engl J Med 1993;329(13):921–925.
- Ferlini A, Sewry C, Melis MA, Mateddu A, Muntoni F. X-linked dilated cardiomyopathy and the dystrophin gene. Neuromuscul Disord 1999;9(5):339–346.
- McNally EM, Mestroni L. Dilated cardiomyopathy: genetic determinants and mechanisms. Circ Res 2017;121(7):731–748.
- Arbelo E, Protonotarios A, Gimeno JR, et al. 2023 ESC Guidelines for the management of cardiomyopathies. Eur Heart J 2023;44(37):3503–3626.
- McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021;42(36):3599–3726.
- Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. Lancet Neurol 2018;17(4):347–361.
- Long L, Mordi IR, Bridges C, et al. Exercise-based cardiac rehabilitation for adults with heart failure. Cochrane Database Syst Rev 2019;1:CD003331.
- Hershberger RE, Givertz MM, Ho CY, et al. Genetic evaluation of cardiomyopathy: a clinical practice resource of the American College of Medical Genetics and Genomics. Genet Med 2018;20(9):899–909.
- Florian A, Ludwig A, Engelen M, et al. Left ventricular systolic function and the pattern of late-gadolinium-enhancement independently and additively predict adverse cardiac events in muscular dystrophy patients. J Cardiovasc Magn Reson 2014;16:81.
Corrections: If something on this page is wrong, out of date or unclear, we want to know. Email reception@inspireclinic.au with the page name and what you believe is incorrect. Substantive corrections are made promptly, and the guide’s version and last-updated date are changed to reflect it.